FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

Johnson & Johnson (JNJ) announced that the FDA granted label expansion to its multiple myeloma (MM) therapy Carvykti (ciltacabtagene autoleucel) for earlier lines of treatment. The therapy has been developed in collaboration with Legend Biotech Corporation (LEGN) .Carvykti is now approved to treat adult patients with relapsed/refractory (r/r) MM who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and who are refractory to Bristol-M ...